Literature DB >> 23190719

Miller Fisher syndrome mimicking ocular myasthenia gravis.

Scott A Anthony1, Matthew J Thurtell, R John Leigh.   

Abstract

PURPOSE.: Miller Fisher syndrome (MFS) is a rare immune-mediated neuropathy that commonly presents with diplopia after the acute onset of complete bilateral external ophthalmoplegia. Ophthalmoplegia is often accompanied by other neurological deficits such as ataxia and areflexia that characterize MFS. Although MFS is a clinical diagnosis, serological confirmation is possible by identifying the anti-GQ1b antibody found in most of the affected patients. We report a patient with MFS who presented with clinical signs suggestive of ocular myasthenia gravis but in whom the correct diagnosis was made on the basis of serological testing for the anti-GQ1b antibody. CASE REPORT.: An 81-year-old white man presented with an acute onset of diplopia after a mild gastrointestinal illness. Clinical examination revealed complete bilateral external ophthalmoplegia and left-sided ptosis. He developed more marked bilateral ptosis, left greater than right, with prolonged attempted upgaze. He was also noted to have a Cogan lid twitch. Same day evaluation by a neuro-ophthalmologist revealed mild left-sided facial and bilateral orbicularis oculi weakness. He had no limb ataxia but exhibited a slightly wide-based gait with difficulty walking heel-to-toe. A provisional diagnosis of ocular myasthenia gravis was made, and anticholinesterase inhibitor therapy was initiated. However, his symptoms did not improve, and serological testing was positive for the anti-GQ1b immunoglobulin G antibody, supporting a diagnosis of MFS. CONCLUSIONS.: Although the predominant ophthalmic feature of MFS is complete bilateral external ophthalmoplegia, it should be recognized that MFS has variable associations with lid and pupillary dysfunction. Such confounding neuro-ophthalmic features require a thorough history, neurological examination, neuroimaging, and serological testing for the anti-GQ1b antibody to arrive at a diagnosis of MFS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23190719      PMCID: PMC3516407          DOI: 10.1097/OPX.0b013e31827717c1

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  26 in total

1.  Clinical features and prognosis of Miller Fisher syndrome.

Authors:  M Mori; S Kuwabara; T Fukutake; N Yuki; T Hattori
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

Review 2.  Neuro-ophthalmology and the Anti-GQ1b antibody syndromes.

Authors:  Robert F Saul
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

3.  Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry.

Authors:  M Koga; M Gilbert; J Li; S Koike; M Takahashi; K Furukawa; K Hirata; N Yuki
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

Review 4.  The immunopathogenesis of Miller Fisher syndrome.

Authors:  H J Willison; G M O'Hanlon
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

Review 5.  Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.

Authors:  N Yuki
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

Review 6.  Anti-ganglioside antibodies and the presynaptic motor nerve terminal.

Authors:  Hugh J Willison; Jaap J Plomp
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

7.  Role of anti-GQ1B antibody in differential diagnosis of acute ophthalmoparesis.

Authors:  E Ece Boylu; R Erdem Toğrol; Mehmet Güney Senol; M Fatih Ozdağ; Mehmet Saraçoğlu
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

8.  Neuromuscular junction dysfunction in Miller Fisher syndrome.

Authors:  M P Silverstein; S Zimnowodzki; J C Rucker
Journal:  Semin Ophthalmol       Date:  2008 May-Jun       Impact factor: 1.975

9.  Acute ophthalmoparesis in the anti-GQ1b antibody syndrome: electrophysiological evidence of neuromuscular transmission defect in the orbicularis oculi.

Authors:  Y L Lo; L L Chan; A Pan; P Ratnagopal
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

10.  Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles.

Authors:  Jing-Xia Liu; Hugh J Willison; Fatima Pedrosa-Domellöf
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-28       Impact factor: 4.799

View more
  4 in total

1.  Miller Fisher Syndrome: A Case Report Highlighting Heterogeneity of Clinical Features and Focused Differential Diagnosis.

Authors:  Ilya V Yepishin; Randall Z Allison; David A Kaminskas; Natalia M Zagorski; Kore K Liow
Journal:  Hawaii J Med Public Health       Date:  2016-07

2.  A Case of Miller Fisher Syndrome and Literature Review.

Authors:  Sumera Bukhari; Javier Taboada
Journal:  Cureus       Date:  2017-02-22

3.  A unique case of Miller Fisher-Guillain-Barré overlap syndrome in a liver transplant recipient.

Authors:  Claudia Ramirez-Sanchez; Rehan Syed; Angela Meier; Jamie Nicole LaBuzetta; Diana J Hylton; Mahnaz Taremi
Journal:  J Neurovirol       Date:  2021-09-22       Impact factor: 2.643

Review 4.  Epidemiology of Ocular Manifestations in Autoimmune Disease.

Authors:  Katie Glover; Deepakkumar Mishra; Thakur Raghu Raj Singh
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.